Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyALMOF 12 3-1 Month Momentum % is N/A% as of Aug. 28, 2026. GuruFocus rates ALMOF with a GF Score™ of 12/100 and a GF Value™ of $0.87 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,384 Biotechnology companies, Alphamab Oncology ranks worse than 68.57% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-28), Alphamab Oncology's 3-1 Month Momentum % is N/A%.
The industry rank for Alphamab Oncology's 3-1 Month Momentum % or its related term are showing as below:
ALMOF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -9.34 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Alphamab Oncology 3-1 Month Momentum % Related Terms
ALMOF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Alphamab Oncology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (ALMOF) has a 3-1 Month Momentum % of N/A% as of Aug. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alphamab Oncology and its competitors. According to the industry distribution chart, Alphamab Oncology ranks #949 out of 1384 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Alphamab Oncology's 3-1 Month Momentum % too high?
Alphamab Oncology's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Alphamab Oncology ranks #949 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alphamab Oncology has a GF Score™ of 12/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #949 out of 1384 companies for 3-1 Month Momentum %. This places Alphamab Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (ALMOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.02 — trading 17.4% above its estimated fair value. The current 3-1 Month Momentum % is N/A%. Alphamab Oncology's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Alphamab Oncology (ALMOF), the current 3-1 Month Momentum % is N/A% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (ALMOF) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of $1.02 is trading 17.4% above its estimated GF Value™ of $0.87.
GuruFocus considers Alphamab Oncology to be Modestly Overvalued.
Key valuation signals for ALMOF:
3-1 Month Momentum %: N/A%
GF Value™: $0.87 vs. price of $1.02 (17.4% above fair value)
No single metric tells the full story. See the ALMOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
12GF Score
Get the complete analysis for ALMOF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMOF has been successfully added to your 
